BioCentury | Jan 15, 2015
Distillery Therapeutics

Therapeutics: Heat shock protein 70 (Hsp70)

...Minneamrita Therapeutics LLC has the Hsp70 inhibitor minnelide in Phase I to treat gastrointestinal cancer. Multimmune GmbH...
BioCentury | Jan 18, 2010
Company News

Boulder Diagnostics Inc., Multimmune deal

...Diagnostics will develop a blood-based heat shock protein 70 (Hsp70) lateral flow point-of-care test for Multimmune...
...of elevated Hsp70 levels with the presence of the tumor specific Hsp70 cell surface marker. Multimmune's...
...colorectal and lung cancers. Financial terms were not disclosed. Boulder Diagnostics Inc. , Boulder, Colo. Multimmune GmbH...
BioCentury | Oct 15, 2009
Distillery Therapeutics

Indication: Cancer

...with vehicle. Next steps include additional preclinical studies to confirm the function of the inhibitors. Multimmune GmbH's...
BioCentury | Sep 4, 2008
Distillery Therapeutics

This Week in Therapeutics

...from Synta Pharmaceuticals Corp. and GlaxoSmithKline plc, is in Phase III testing to treat melanoma. Multimmune GmbH...
Items per page:
1 - 4 of 4
BioCentury | Jan 15, 2015
Distillery Therapeutics

Therapeutics: Heat shock protein 70 (Hsp70)

...Minneamrita Therapeutics LLC has the Hsp70 inhibitor minnelide in Phase I to treat gastrointestinal cancer. Multimmune GmbH...
BioCentury | Jan 18, 2010
Company News

Boulder Diagnostics Inc., Multimmune deal

...Diagnostics will develop a blood-based heat shock protein 70 (Hsp70) lateral flow point-of-care test for Multimmune...
...of elevated Hsp70 levels with the presence of the tumor specific Hsp70 cell surface marker. Multimmune's...
...colorectal and lung cancers. Financial terms were not disclosed. Boulder Diagnostics Inc. , Boulder, Colo. Multimmune GmbH...
BioCentury | Oct 15, 2009
Distillery Therapeutics

Indication: Cancer

...with vehicle. Next steps include additional preclinical studies to confirm the function of the inhibitors. Multimmune GmbH's...
BioCentury | Sep 4, 2008
Distillery Therapeutics

This Week in Therapeutics

...from Synta Pharmaceuticals Corp. and GlaxoSmithKline plc, is in Phase III testing to treat melanoma. Multimmune GmbH...
Items per page:
1 - 4 of 4